These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 21462517)
1. [Treatment of gout in patients with chronic kidney disease]. Bertrand J; Genevay S; Saudan P Rev Med Suisse; 2011 Mar; 7(284):483-6, 488-9. PubMed ID: 21462517 [TBL] [Abstract][Full Text] [Related]
2. Update on gout and hyperuricemia. Baker JF; Schumacher HR Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378 [TBL] [Abstract][Full Text] [Related]
3. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094 [TBL] [Abstract][Full Text] [Related]
4. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N; Kumar S; Stamp L; Gow P J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857 [TBL] [Abstract][Full Text] [Related]
5. [Allopurinol efficacy in patients with tophus gout and chronic renal failure]. Iakunina IA; Barskova VG; Nasonova VA Ter Arkh; 2006; 78(6):88-91. PubMed ID: 16881370 [No Abstract] [Full Text] [Related]
6. Febuxostat: a new treatment for hyperuricaemia in gout. Edwards NL Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778 [TBL] [Abstract][Full Text] [Related]
7. Current and future therapeutic options for the management of gout. Whelton A Am J Ther; 2010; 17(4):402-17. PubMed ID: 20562597 [TBL] [Abstract][Full Text] [Related]
13. Hyperuricemia, gout, and cardiovascular disease--an important "muddle". Keenan RT; Pillinger MH Bull NYU Hosp Jt Dis; 2009; 67(3):285-90. PubMed ID: 19852752 [TBL] [Abstract][Full Text] [Related]
14. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369 [TBL] [Abstract][Full Text] [Related]
15. [Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects]. Yamanaka H Nihon Rinsho; 2003 Jan; 61 Suppl 1():202-8. PubMed ID: 12629718 [No Abstract] [Full Text] [Related]
16. Drug therapy reviews: pathogenesis and clinical management of hyperuricemia and gout. Mangini RJ Am J Hosp Pharm; 1979 Apr; 36(4):497-504. PubMed ID: 433935 [No Abstract] [Full Text] [Related]